Indrayani Biotech Limited (BOM:526445)
India · Delayed Price · Currency is INR 8.10
+0.65 (8.72%)
At close: Mar 24, 2026
Indrayani Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,506 | 1,302 | 1,662 | 1,629 | 615.72 | 210.88 |
Other Revenue | - | - | - | 0.02 | 0.11 | 1.03 |
| 1,506 | 1,302 | 1,662 | 1,629 | 615.82 | 211.91 | |
Revenue Growth (YoY) | 21.44% | -21.66% | 2.02% | 164.57% | 190.60% | -57.53% |
Cost of Revenue | 1,108 | 845.68 | 989.28 | 1,039 | 414.11 | 160.71 |
Gross Profit | 398.59 | 456.61 | 672.98 | 590.2 | 201.72 | 51.2 |
Selling, General & Admin | 177.09 | 221.23 | 258.36 | 252.87 | 107.75 | 66.86 |
Other Operating Expenses | 146.62 | 148.06 | 170.03 | 157.06 | 25.2 | 32.81 |
Operating Expenses | 338.24 | 402.97 | 466.39 | 443.41 | 139.54 | 104.25 |
Operating Income | 60.35 | 53.64 | 206.58 | 146.79 | 62.17 | -53.05 |
Interest Expense | -125.52 | -107.17 | -98.83 | -49.99 | -18.26 | -19.08 |
Interest & Investment Income | 6.33 | 6.33 | 1.57 | 26.09 | 1.14 | 1.59 |
Earnings From Equity Investments | - | - | - | - | - | 0.03 |
Other Non Operating Income (Expenses) | -10.24 | -10.24 | 0.42 | 4.65 | -0.54 | -0.54 |
EBT Excluding Unusual Items | -69.08 | -57.44 | 109.74 | 127.54 | 44.52 | -71.05 |
Asset Writedown | - | - | - | -5 | - | - |
Other Unusual Items | - | - | - | 0.52 | - | -41.1 |
Pretax Income | -69.08 | -57.44 | 109.74 | 123.06 | 44.52 | -112.14 |
Income Tax Expense | 4.34 | 3.64 | 5.52 | 3.75 | 0.12 | - |
Earnings From Continuing Operations | -73.42 | -61.08 | 104.22 | 119.31 | 44.4 | -112.14 |
Minority Interest in Earnings | 45.51 | 45.51 | -40.58 | -31.94 | -0.46 | - |
Net Income | -27.91 | -15.57 | 63.65 | 87.37 | 43.93 | -112.14 |
Net Income to Common | -27.91 | -15.57 | 63.65 | 87.37 | 43.93 | -112.14 |
Net Income Growth | - | - | -27.15% | 98.87% | - | - |
Shares Outstanding (Basic) | - | 46 | 36 | 34 | 34 | 36 |
Shares Outstanding (Diluted) | - | 46 | 46 | 43 | 34 | 36 |
Shares Change (YoY) | - | - | 4.74% | 27.02% | -3.86% | 878.95% |
EPS (Basic) | - | -0.34 | 1.75 | 2.55 | 1.28 | -3.15 |
EPS (Diluted) | - | -0.35 | 1.40 | 2.01 | 1.28 | -3.15 |
EPS Growth | - | - | -30.35% | 57.03% | - | - |
Free Cash Flow | - | -81.17 | -466.56 | -53.4 | 29.22 | -4.4 |
Free Cash Flow Per Share | - | -1.78 | -10.25 | -1.23 | 0.85 | -0.12 |
Gross Margin | 26.46% | 35.06% | 40.49% | 36.22% | 32.76% | 24.16% |
Operating Margin | 4.01% | 4.12% | 12.43% | 9.01% | 10.10% | -25.04% |
Profit Margin | -1.85% | -1.20% | 3.83% | 5.36% | 7.13% | -52.92% |
Free Cash Flow Margin | - | -6.23% | -28.07% | -3.28% | 4.75% | -2.08% |
EBITDA | 90.75 | 87.32 | 244.64 | 180.26 | 68.77 | -48.47 |
EBITDA Margin | 6.02% | 6.71% | 14.72% | 11.06% | 11.17% | -22.87% |
D&A For EBITDA | 30.4 | 33.68 | 38.05 | 33.47 | 6.59 | 4.58 |
EBIT | 60.35 | 53.64 | 206.58 | 146.79 | 62.17 | -53.05 |
EBIT Margin | 4.01% | 4.12% | 12.43% | 9.01% | 10.10% | -25.04% |
Effective Tax Rate | - | - | 5.03% | 3.05% | 0.28% | - |
Revenue as Reported | 1,571 | 1,334 | 1,674 | 1,674 | 617.93 | 213.53 |
Advertising Expenses | - | 7.08 | 8.19 | 8.89 | 1.65 | 3.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.